Showing results (681-690 of 740) with videos related to

Sort By:
Pageof 74
Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society|March 31, 2016
Longterm results of liver transplantation from donation after circulatory deathJoris J Blok, Olivier Detry, Hein Putter, et al.
Applied Radiation and Isotopes : Including Data, Instrumentation and Methods for Use in Agriculture, Industry and Medicine|September 14, 2017
Metrology for decommissioning nuclear facilities: Partial outcomes of joint research project within the European Metrology Research ProgramJiri Suran, Petr Kovar, Jana Smoldasova, et al.
Nutrition, Metabolism, and Cardiovascular Diseases : NMCD|June 9, 2014
Mechanisms of stress, energy homeostasis and insulin resistance in European adolescents--the HELENA studyI Huybrechts, T De Vriendt, C Breidenassel, et al.
Archives of Toxicology|December 11, 2012
Proteomic and metabolomic responses to connexin43 silencing in primary hepatocyte culturesMathieu Vinken, Michaël Maes, Rachel Cavill, et al.
Critical Reviews in Oncology/Hematology|October 18, 2022
Cancer-related cognitive impairment in non-CNS cancer patients: Targeted review and future action plans in Europe, Charlotte Sleurs, Ali Amidi, et al.
Annals of Surgery|October 22, 2019
Procedural Surgical RCTs in Daily Practice: Do Surgeons Adopt Or Is It Just a Waste of Time?Christian E Oberkofler, Jacob F Hamming, Roxane D Staiger, et al.
BMJ Open|October 12, 2017
Hypothermic oxygenated machine perfusion (HOPE) for orthotopic liver transplantation of human liver allografts from extended criteria donors (ECD) in donation after brain death (DBD): a prospective multicentre randomised controlled trial (HOPE ECD-DBD)Zoltan Czigany, Wenzel Schöning, Tom Florian Ulmer, et al.
Nature Communications|June 29, 2018
Sustained SREBP-1-dependent lipogenesis as a key mediator of resistance to BRAF-targeted therapyAli Talebi, Jonas Dehairs, Florian Rambow, et al.
NAM Journal|June 29, 2026
SCCS opinion on biphenyl-2-ol and sodium 2-biphenylolate used in cosmetic products (CAS/EC No. 90-43-7/201-993-5 and 132-27-4/205-055-6)- SCCS/1669/24Ulrike Bernauer Rapporteur, Laurent Bodin, Qasim Chaudhry, et al.
ESMO Open|April 10, 2026
Efficacy and safety of regorafenib in patients with advanced pretreated melanoma: results of the RegoMel phase II clinical trialI Dirven, C Bertels, Y Moreels, et al.
Pageof 74